Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 1 and 2 bp insertion in exon 1 and Insertion of the selection cassette in exon 1
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-NDUFAF8, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
C17orf89 also known as Chromosome 17 Open Reading Frame 89 is a protein with a mass of about 44 kDa. This protein locates itself in the cytoplasm and is expressed in various tissues including the liver kidney and heart. C17orf89 contains no known enzymatic activity but it suggests a role in cellular processes. Studies have detected its presence where it might interact with other proteins involved in cellular metabolism.
Biological function summary
C17orf89 has roles involving cellular structural integrity and signaling. It does not belong to any known protein complex but it may still coordinate actions within the cell membrane. Through these functions C17orf89 helps maintain an optimal cellular environment supporting the function of cells and tissues. Although its precise biological functions remain studied its interactions indicate involvement in critical cellular maintenance tasks.
Pathways
The protein interacts with elements of the insulin signaling pathway and possibly the mTOR pathway influencing metabolic processes. In these pathways C17orf89 interacts with proteins like insulin receptor substrate 1 (IRS1) and the mammalian target of rapamycin (mTOR). These interactions suggest a role in nutrient sensing and cellular growth responses enabling proper cellular adaptation to environmental changes.
C17orf89 has been associated with metabolic disorders and cardiovascular diseases. Its connection to proteins such as IRS1 highlights its potential link to insulin resistance a feature of type 2 diabetes. Additionally altered expression or function of C17orf89 could influence the development of heart disease through its role in cellular signaling and metabolism. As research continues understanding the nuances of these interactions could offer new insights into disease mechanisms and therapeutic targets.
